Biocept (BIOC) Reports Q4 Loss of $0.24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Biocept (BIOC) Reports Q4 Loss of $0.24
March 9, 2016 4:05 PM EST
SAN DIEGO, March 9, 2016 /PRNewswire/ --Â Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the diagnosis and treatment of cancer, today reported financial results for the three and 12 months ended December 31, 2015, and provided an update on business progress.Â
"Commercial samples reached a record high of 584 for the fourth quarter, up 32% from the third quarter, indicating that our tests are increasingly being used by physicians to assist with making... More
March 9, 2016 7:00 AM EST
SAN DIEGO, March 9, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing assays for liquid biopsies to improve the detection and treatment of cancer, announces an agreement with preferred provider organization (PPO) network FedMed. FedMed members now have improved network access to Biocept's proprietary Target Selector liquid biopsy testing.Â
FedMed was founded in 2000 with corporate headquarters located in Gaithersburg, Maryland. FedMed operates a proprietary PPO consisting of more than 550,000 physicians, 4,000 hospitals and 60,000 ancillary care providers nationwide. More... More
